Consolidated Statements of Cash Flows (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash Flows from Operating Activities
Net income	$ 4,684.8	$ 4,088.6	$ 4,347.7
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization	1,445.6	1,462.2	1,373.6
Change in deferred income taxes	285.9	126.0	(268.5)
Stock-based compensation expense	144.9	141.5	147.4
Impairment charges, indefinite lived intangibles	0	205.0	151.5
Acquired in-process research and development, net of tax	37.1	0	252.2
Income related to termination of the exenatide collaboration with Amylin	(495.4)	(787.8)	0
Other operating activities, net	25.1	120.5	(17.8)
Changes in operating assets and liabilities, net of acquisitions
Receivables - (increase) decrease	(152.7)	361.8	(188.8)
Inventories - (increase) decrease	(286.5)	(307.9)	203.1
Other assets - (increase) decrease	116.5	231.0	642.7
Accounts payable and other liabilties-increase (decrease)	(70.3)	(336.1)	591.4
Net Cash Provided by Operating Activities	5,735.0	5,304.8	7,234.5
Cash Flows from Investing Activities
Purchases of property and equipment	(1,012.1)	(905.4)	(672.0)
Disposals of property and equipment	179.4	22.0	25.3
Proceeds from sales and maturities of short-term investments	3,320.1	2,547.5	1,807.9
Purchases of short-term investments	(1,531.0)	(2,172.4)	(2,058.8)
Proceeds from sales and maturities of noncurrent investments	11,235.0	4,355.7	2,138.5
Purchases of noncurrent investments	(14,041.9)	(7,618.6)	(4,459.4)
Purchase of product rights	(24.1)	(138.8)	(632.9)
Purchases of in-process research and development	(57.1)	0	(388.0)
Cash paid for acquisitions, net of cash acquired	(43.7)	(199.3)	(307.8)
Net change in loan to collaboration partner	0	165.0	(165.0)
Proceeds from prepayment of revenue-sharing obligation	0	1,212.1	0
Other investing activities, net	(97.4)	(100.6)	(112.2)
Net Cash Used for Investing Activities	(2,072.8)	(2,832.8)	(4,824.4)
Cash Flows from Financing Activities
Dividends paid	(2,120.7)	(2,187.4)	(2,180.1)
Net change in short-term borrowings	0	0	(134.1)
Repayments of long-term debt	(10.5)	(1,511.1)	(61.7)
Purchases of common stock	(1,698.1)	(721.1)	0
Other financing activities, net	0	0	6.0
Net Cash Used for Financing Activities	(3,829.3)	(4,419.6)	(2,369.9)
Effect of exchange rate on cash and cash equivalents	(21.5)	43.9	(110.9)
Net decrease in cash and cash equivalents	(188.6)	(1,903.7)	(70.7)
Cash and cash equivalents at beginning of year	4,018.8	5,922.5	5,993.2
Cash and Cash Equivalents at End of Year	$ 3,830.2	$ 4,018.8	$ 5,922.5